THE SATIETY SIGNAL
Cagrilintide
Long-acting appetite suppressant for serious weight loss
Also known as: Acylated amylin analog
Overview
Cagrilintide is a modified version of amylin, a hormone your pancreas releases after eating. It tells your brain you're full, slows stomach emptying, and improves blood sugar control. Combined with GLP-1 drugs like semaglutide, it can produce dramatic weight loss results (up to 15% body weight).
Key Benefits & Mechanisms
Appetite Control
Activates satiety centers in the brain to reduce hunger
Gastric Slowing
Delays stomach emptying so you feel full longer
Blood Sugar
Suppresses glucagon and improves insulin sensitivity
Dosing Guide
Dosage
2.4 mg once weekly (subcutaneous)
Schedule
weekly
Cycle
8+ weeks (ongoing treatment)
Pro Tip
Often combined with semaglutide for enhanced effects; inject on same day each week
Safety Profile
Good Safety
Good
Well-tolerated in clinical trials. Being developed by Novo Nordisk.
Still in clinical development. Works best when combined with GLP-1 agonists.
Possible Side Effects
What to Expect
Week 1
Reduced appetite and food intake
Week 4-8
Noticeable weight loss (3-5%)
Week 12+
Significant weight loss (10-15% with GLP-1 combo)
Appetite reduction within first week; significant weight loss by 8-12 weeks.
Who Is This For
Research References
Related Peptides
ACE-031
THE MUSCLE UNLEASHED
Block the muscle-limiting signal and unlock serious gains
BAM-15
THE CALORIE BURNER
Make your cells burn more fuel - mitochondrial uncoupling for fat loss
IGF-LR3
THE MUSCLE MAXIMIZER
Extended-release IGF-1 for powerful muscle growth
L-Carnitine
THE FAT TRANSPORTER
Fat-burning amino acid for energy and mitochondrial health
Mazdutide
THE DUAL ACTIVATOR
Next-gen weight loss with dual hormone action
Pancragen
THE PANCREAS PROTECTOR
Restore pancreatic function and improve blood sugar control
Ready to Start Your Peptide Journey?
Track your protocols, get guided reconstitution, and access our vetted vendor network — all in one app.
Download The Peptide App